Results from a real-world study evaluating rivaroxaban (Xarelto; Janssen) in newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session.
The study included patients from the Optum Clinformatics Database who started treatment within 30 days of their first NVAF diagnosis between 2011–2017; a total of 20,596 patients taking rivaroxaban and 20,431 patients taking warfarin were included. Both groups had similar baseline characteristics including comorbidity index and CHA2DS2-VASc scores.
Patients were followed from initiation to the end of study, death or stroke diagnosis (mean follow-up 23 months [rivaroxaban] and 29 months [warfarin]). Stroke was identified in the hospital inpatient setting using ICD-9/-10 codes, and mortality was assessed within 30 days and any time post-stroke.
Results showed that compared with warfarin, rivaroxaban significantly reduced overall strokes (all severities) by 18% (P=.0005). Specifically, treatment with rivaroxaban reduced the risk of major stroke by 47% (P=.0059), moderate stroke by 5% (P=.5178), and minor stroke by 18% (P=.0240). In addition, rivaroxaban significantly reduced the risk of post-stroke mortality at 30 days by 59% (P<.0001) and at any time post-stroke by 22% (P=.0248).
Xarelto, a Factor Xa inhibitor, is currently approved to treat and to reduce the risk of various thromboembolic disorders.
For more information call (800) 526-7736 or visit Xarelto.com.
This article originally appeared on MPR